(Reuters) - U.S. healthcare group Johnson & Johnson (JNJ.N) launched its long-awaited 1.75 billion euro ($2.3 billion) bid for Crucell (CRCL.AS), despite some investor opposition and the Dutch biotech's vaccine production problems.
J&J said in September it would bid 24.75 euros per share for the outstanding shares in Crucell -- whose vaccines protect against childhood diseases including whooping cough and diphtheria...
"...Short term it's the childhood vaccines, but over the next five to six years it's the influenza vaccine," that will generate huge growth for J&J given the worldwide demand for influenza vaccines, Muller added. Read the full article HERE.
TrackBack URL for this entry:
Listed below are links to weblogs that reference J&J eyes vaccine market with $2.3 billion Crucell bid: